A review of chemotherapy for metastatic colon cancer;Revisión del tratamiento quimioterápico del cáncer de colon metastásico

Farmacia Hospitalaria

Volumn 30, Issue 6, 2006, Pages 359-369

  Díez Fernández, Raúl ^a   Salinas Hernandez P ^a   Giron Duch C ^a  

^a HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

Author keywords

Bevacizumab; Capecitabine; Cetuximab; Colorectal cancer; Fluorouracil; Irinotecan; Neoplastic metastasis; Oxaliplatin; Raltitrexed

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; RALTITREXED;

CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; DRUG SAFETY; EMBASE; HUMAN; INFORMATION RETRIEVAL; META ANALYSIS; METASTASIS; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW;

EID: 33846804391     PISSN: 11306343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1130-6343(06)74007-7     Document Type: Review

References (41)

1. López-Abente G, Pollán M, Escolar A, Errezola M, Abraira V. Atlas de mortalidad por cáncer y otras causas en España, 1978-1992 [Monografía en internet]. Madrid: Instituto de Salud Carlos III; 2001. Disponible en: http://www2.uca.es/hospital/atlas92/www/introdu.html
2. Centro Nacional de Epidemiología. Mortalidad por cáncer en España. Años 1996-2001. Web del Centro Nacional de Epidemiología, Área de Epidemiología Ambiental y Cáncer. Disponible en: http://cne.isciii.es/
3. American Cancer Society. Junio 2006. Disponible en: http://www.cancer. org/docroot/CRI/CRI_2_3x.asp?dt=10
4. Meta-analysis group in cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer. J Clin Oncol 1998; 16 (1): 301-8.
5. Piedbois P, Michiels S, for the Meta-analysis Group in Cancer. Survival benefit of 5FU/LV over 5FU bolus in patients with advanced colorectal cancer: An updated meta-analysis based on 2751 patients (abstract). Proc Am Soc Clin Oncol 2003; 22: 294a.
6. Meta-Analysis Group in Cancer. Modulation o fluorouracil by leucovorin in patients with advanced colorectal cancer: An updated meta-analysis. J Clin Oncol 2004; 22: 3766-75.
7. Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III Study. J Clin Oncol 2001; 19: 4097-106.
8. Hoff PM, Ansari R, Batist O, Cox J, Kocha W, Kuperminc M, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 2001; 19: 2282-92.
9. Douillard JY, Hoff PM, Skillings JR, Eisenberg P, Davidson N, Harper P, et al. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002; 20: 3605-16.
10. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer [published erratum appears in Lancet 1998; 352 (9140): 1634]. Lancet 1998; 352: 1407-12.
11. Cunningham D, Pyrhonen S, James RD, Punt C, Hickish TF, Heikkila R, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413-8.
12. Saltz LB, Cox JV, Blanke C, Rosen LS, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-1004.
13. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000; 355: 1041-7.
14. Kohne CH, van Cutsem E, Wils J, Bokemeyer C, El-Serafi M, Lutz MP, et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 2005; 23: 4856-65.
15. Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-47.
16. Rotehnberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of phase III trial. J Clin Oncol 2003; 21: 2059-69.
17. Rothenberg ML, Oza AM, Burger B, Berlin J, Marshall JL, Ramanathan RK, et al. Final results of a phase III trial of 5-FU/Leucovorin versus oxaliplatin versus the combination in patients with metastatic colorectal cancer following irinotecan, 5-FU and leucovorin (abstract). Proc Am Soc Clin Oncol 2003; 22: 252a.
18. Goldberg R, Sargent D, Morton R, Fuchs C, Ramanathan R, Williamson S, et al. A randomized contolled trial of fluorouracil plus leucovorin, irinotecan and oxaliplatino combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30.
19. Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005; 23: 4866-75.
20. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study. J Clin Oncol 2004; 22: 229-37.
21. Cassidy J, Tabernero J, Twelves C, Brunet R, Cutts C, Conroy T, et al. XELOX (capecitabine plus oxaliplatin): Active first-line therapy for patients wilh metastatic colorectal cancer. J Clin Oncol 2004; 22: 2084-91.
22. Scheithauer W, Kornek GV, Raderer M, Schüll B, Schmid K, Kovats E, et al. Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2003; 21: 1307-12.
23. Zeuli M, Nardoni C, Pino MS, Gamucci T, Gabriele A, Ferraseri V, et al. Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer. Ann Oncol 2003; 14: 1378-82.
24. Shields AF, Zalupski MM, Marshall JL, Meropol, NJ. Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine. Cancer 2004; 100: 531-7.
25. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan and oxaliplatin in the course o treatment. J Clin Oncol 2004; 22: 1209-14.
26. National Institute for Health and Clinical Excellence. TA93 colorectal cancer (advanced) - irinotecan, oxaliplatin and raltitrexed (review). August 2005. Available at: www.nice.org.uk
27. Maughan TS, James RD, Kerr DJ, Ledermann JA, McArdle C, Seymour MT, et al. Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: A multicentre randomised trial. Lancet 2002; 359: 1555-63.
28. Saltz LB, Meropol NJ, Loehrer PJ, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-8.
29. Saltz L, Rubin M, Hochster H, Tchekmeydian NS, Waksal H, Needle M, et al. Cetuximab (IMC-225) plus irinotecan is active in CPT-11-refractory colorectal cancer that expresses epidermal growth factor receptor (abstract). Proc Am Soc Clin Oncol 2001; 20: 3a.
30. Cunningham D, Humblet Y, Siena S, Khayat D. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-45.
31. Scartozzi M, Bearzi I, Berardi R, Mandolesi A, Fabris G, Cascinu S. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: Implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol 2004; 22: 4772-8.
32. Chung KY, Shia J, Kemeny N, Shah M, Schwartz GK, Tse A, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23: 1803-10.
33. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-5.
34. Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht R, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol 2005; 23: 3697-705.
35. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-12.
36. Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, et al. Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005; 23: 3502-8.
37. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005; 23: 3706-12.
38. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200 (abstract). J Clin Oncol 2005; 23: 1s.
39. Grothey A, Deschler B, Kroening H. Phase III study of bolus 5-fluorouracil (5-FU)/ folinic acid (FA) (Mayo) vs. weekly high-dose 24h 5-FU infusion/FA + oxaliplatin (OXA) in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2002; 21: 129a (abstr. 512).
40. Nacional Comprehensive Cancer Network: Practice Guidelines in Oncology, Colon Cancer; 26/06/06. Available at: www.nccn.org
41. Van Cutsem EJD, Kataja VV; ESMO Guidelines Task Force. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of advanced colorectal cancer. An Oncol 2005; 16 (Supl.): i18-9.